Clinical trial: Randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 5, 2008, Pages 574-580

  Rossignol, J F ^b,c   Kabil, S M ^d   El Gohary, Y ^e   Elfert, A ^f   Keeffe, E B ^a,b,c  

^a Romark Institute for Medical Research ^*  (United States)

^b Romark Institute for Medical Research   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BENHA UNIVERSITY   (Egypt)

^e ALEXANDRIA UNIVERSITY   (Egypt)

^f TANTA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

NITAZOXANIDE; PLACEBO; VIRUS RNA;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM ULCER; EGYPT; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MELENA; METABOLISM; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT RESPONSE;

ADULT; AGED; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; EGYPT; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; RNA, VIRAL; TABLETS; THIAZOLES; TREATMENT OUTCOME;

EID: 48449084880     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03781.x     Document Type: Article

References (11)

1. World Health Organization. Hepatitis C. Fact sheet Number 164, revised October 2000. Available at: http://www.who.int/mediacentre/factsheets/fs164/en (accessed 2 May 2008).
2. Egyptian Ministry of Health. Egyptian Ministry of Health Annual Report. 2007. Available at: http://www.mohp.gov.eg/main (accessed 2 May 2008).
3. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004 39 : 1147 71.
4. Kamal SM, Nasser IA. Hepatitis C genotype 4: what we know and what we don't yet know. Hepatology 2008 47 : 1371 83.
5. Anderson VR, Curran MP. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs 2007 67 : 1947 67.
6. Korba BE, Montero AB, Farrar K, et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res 2008 77 : 56 63.
7. Rossignol JF, Kabil SM, El-Gohary Y, Keeffe EB. Randomized double blind placebo-controlled trial of nitazoxanide in the treatment of patients with chronic hepatitis C genotype 4 [abstract]. J Hepatol 2008 48 (Suppl. 2 S311 2.
8. Knodell RG, Ishak KJ, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1991 1 : 431 5.
9. Goodman ZK, Ishak JG. Histopathology of hepatitis C virus infection. Sem Liv Dis 1995 15 : 71 81.
10. Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB. Randomized controlled trial of nitazoxanide-peginterferon-ribavirin, nitazoxanide-peginterferon and peginterferon-ribavirin in the treatment of patients with chronic hepatitis C genotype 4 [abstract]. J Hepatol 2008 48 (Suppl. 2 S30.
11. Korba BE, Glenn JS, Ayers MS, Rossignol JF. Studies of the potential for resistance to nitazoxanide or tizoxanide [abstract]. J Hepatol 2008 48 (Suppl. 2 S11.